JNJ-64281802

DRUG3 trials

Sponsors

Janssen Research & Development, LLC

Conditions

DengueHealthy

Phase 1

A Study of JNJ-64281802 in Healthy Adult Participants

CompletedNCT05201937

Janssen Research & Development, LLCHealthy

Start: 2022-02-23End: 2022-12-11Updated: 2025-03-30

Phase 2

A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever

TerminatedNCT04906980

Janssen Research & Development, LLCDengue

Start: 2022-01-24End: 2023-03-21Updated: 2024-03-01

A Study of JNJ-64281802 for the Prevention of Dengue Infection

TerminatedNCT05201794

Janssen Research & Development, LLCDengue

Start: 2023-02-22End: 2024-06-26Updated: 2025-07-31

Related Papers

Therapeutic Approaches Against Dengue Virus: Current Status of Vaccines, Antivirals, and Monoclonal Antibodies.

2026-06-08

Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ‐1802) in Healthy Adult Participants

Clinical Pharmacology in Drug Development2025-07-151 citations